FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2044468104> ?p ?o ?g. }

• W2044468104 endingPage "298" @default.
• W2044468104 startingPage "290" @default.
• W2044468104 abstract "Reliable and objective markers of neuronal function and pathology that can directly assess the effects of neuroprotective treatments in the brain are urgently needed for clinical trials in neurodegenerative diseases. Here we assessed the sensitivity of high field proton magnetic resonance spectroscopy (1H MRS) to monitor reversal of neurodegeneration by taking advantage of a well characterized conditional mouse model of spinocerebellar ataxia type 1 (SCA1), where the cerebellar pathology and ataxic phenotype are reversible by doxycycline administration. Transgene expression was suppressed by feeding the mice with chow that contains doxycycline from 6 to 12 weeks of age in an early stage group and from 12 to 24 weeks in a mid-stage group. Cerebellar neurochemical profiles of treated and untreated conditional mice were measured at 9.4 tesla (T) before and after treatment and compared to those of wild type (WT) controls, as well as to histology measures (molecular layer thickness in the primary fissure and a global pathological severity score). Concentrations of N-acetylaspartate (NAA) and myo-inositol in the treated mice trended toward normalization to WT levels in both the early and mid-stage groups. The NAA-to-myo-inositol ratio was significantly different between the treated vs. untreated SCA1 mice and demonstrated partial reversal to WT values both at early and mid-stage, consistent with the histological measures. Taurine and total creatine levels were completely normalized in early and mid-stage treatment groups, respectively. The MRS markers were a more sensitive measure of treatment response than the histological measures from the same volume-of-interest in the early stage group. NAA, myo-inositol and taurine levels were significantly correlated with the histology measures in data combined from all groups. These data demonstrate that MRS markers reliably detect rescue from neuronal pathology and imply that the neurochemical levels measured by MRS accurately reflect treatment efficacy. Therefore this study presents an important step in validating MRS biomarkers as potential surrogate markers to evaluate therapeutics in pre-clinical and clinical trials in SCA1." @default.
• W2044468104 created "2016-06-24" @default.
• W2044468104 creator A5005157144 @default.
• W2044468104 creator A5005772078 @default.
• W2044468104 creator A5026753938 @default.
• W2044468104 creator A5038085079 @default.
• W2044468104 creator A5046940016 @default.
• W2044468104 creator A5069626194 @default.
• W2044468104 creator A5082698708 @default.
• W2044468104 date "2011-12-01" @default.
• W2044468104 modified "2023-10-13" @default.
• W2044468104 title "In vivo monitoring of recovery from neurodegeneration in conditional transgenic SCA1 mice" @default.
• W2044468104 cites W1485144031 @default.
• W2044468104 cites W1501756216 @default.
• W2044468104 cites W1552654146 @default.
• W2044468104 cites W1750171938 @default.
• W2044468104 cites W1970130998 @default.
• W2044468104 cites W1990301502 @default.
• W2044468104 cites W1993419607 @default.
• W2044468104 cites W1997883336 @default.
• W2044468104 cites W2010055907 @default.
• W2044468104 cites W2014480794 @default.
• W2044468104 cites W2017009791 @default.
• W2044468104 cites W2023798788 @default.
• W2044468104 cites W2025265926 @default.
• W2044468104 cites W2028524574 @default.
• W2044468104 cites W2038979894 @default.
• W2044468104 cites W2041967761 @default.
• W2044468104 cites W2043829182 @default.
• W2044468104 cites W2044244805 @default.
• W2044468104 cites W2048052925 @default.
• W2044468104 cites W2050557825 @default.
• W2044468104 cites W2054401501 @default.
• W2044468104 cites W2057327829 @default.
• W2044468104 cites W2060005442 @default.
• W2044468104 cites W2076681561 @default.
• W2044468104 cites W2086465414 @default.
• W2044468104 cites W2105182553 @default.
• W2044468104 cites W2106774052 @default.
• W2044468104 cites W2109195157 @default.
• W2044468104 cites W2124622312 @default.
• W2044468104 cites W2126278820 @default.
• W2044468104 cites W2133141500 @default.
• W2044468104 cites W2134483481 @default.
• W2044468104 cites W2152311397 @default.
• W2044468104 cites W2154108863 @default.
• W2044468104 cites W2160842963 @default.
• W2044468104 cites W2165377658 @default.
• W2044468104 cites W2168936817 @default.
• W2044468104 cites W2169307072 @default.
• W2044468104 cites W2171062663 @default.
• W2044468104 cites W2255469197 @default.
• W2044468104 cites W2405874464 @default.
• W2044468104 doi "https://doi.org/10.1016/j.expneurol.2011.09.021" @default.
• W2044468104 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3221464" @default.
• W2044468104 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21963649" @default.
• W2044468104 hasPublicationYear "2011" @default.
• W2044468104 type Work @default.
• W2044468104 sameAs 2044468104 @default.
• W2044468104 citedByCount "30" @default.
• W2044468104 countsByYear W20444681042012 @default.
• W2044468104 countsByYear W20444681042013 @default.
• W2044468104 countsByYear W20444681042014 @default.
• W2044468104 countsByYear W20444681042015 @default.
• W2044468104 countsByYear W20444681042016 @default.
• W2044468104 countsByYear W20444681042018 @default.
• W2044468104 countsByYear W20444681042019 @default.
• W2044468104 countsByYear W20444681042020 @default.
• W2044468104 countsByYear W20444681042021 @default.
• W2044468104 countsByYear W20444681042022 @default.
• W2044468104 crossrefType "journal-article" @default.
• W2044468104 hasAuthorship W2044468104A5005157144 @default.
• W2044468104 hasAuthorship W2044468104A5005772078 @default.
• W2044468104 hasAuthorship W2044468104A5026753938 @default.
• W2044468104 hasAuthorship W2044468104A5038085079 @default.
• W2044468104 hasAuthorship W2044468104A5046940016 @default.
• W2044468104 hasAuthorship W2044468104A5069626194 @default.
• W2044468104 hasAuthorship W2044468104A5082698708 @default.
• W2044468104 hasBestOaLocation W20444681042 @default.
• W2044468104 hasConcept C102230213 @default.
• W2044468104 hasConcept C104317684 @default.
• W2044468104 hasConcept C126322002 @default.
• W2044468104 hasConcept C134018914 @default.
• W2044468104 hasConcept C141035611 @default.
• W2044468104 hasConcept C142724271 @default.
• W2044468104 hasConcept C169760540 @default.
• W2044468104 hasConcept C170493617 @default.
• W2044468104 hasConcept C207886595 @default.
• W2044468104 hasConcept C25498285 @default.
• W2044468104 hasConcept C25876315 @default.
• W2044468104 hasConcept C2776925932 @default.
• W2044468104 hasConcept C2777427919 @default.
• W2044468104 hasConcept C2779134260 @default.
• W2044468104 hasConcept C2779500118 @default.
• W2044468104 hasConcept C2779701627 @default.
• W2044468104 hasConcept C2779896295 @default.
• W2044468104 hasConcept C2780906641 @default.
• W2044468104 hasConcept C515207424 @default.

• next